Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P100044/S059

Propel, Propel Mini (including Propel Mini with Straight Delivery System), and Propel Contour Sinus Implants

Intersect Ent. · Decision date Jul 31, 2026

FDA DECISIONP100044/S059

What did the FDA approve?

FDA records P100044/S059 as a supplement to PMA P100044, with the supplement type “135 Review Track For 30-Day Notice”. The recorded decision is approval, dated Jul 31, 2026.

FDA approval order statement

approval for an alternate analytical testing site for analytical lot release and stability testing for the Propel family of products
Regulatory pathway
PMA supplement
Supplement type
135 Review Track For 30-Day Notice
Clinical specialty
Ear, Nose, Throat
Decision date
Jul 31, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P100044/S059
Regulatory pathway
PMA supplement
Product code
OWO
Decision code
APPR
Decision date
Jul 31, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Drug-eluting sinus stent.

Product code
OWO
FDA device class
3

For the original device and its historical approval scope, see PMA P100044. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P100044/S058 · Related supplement

    Propel Contour Sinus Implant

  2. P100044/S059 received

    Application receipt date recorded by FDA.

  3. P100044/S059 · FDA decision

    135 Review Track For 30-Day Notice

Timeline entries are records held by MedtechLedger for P100044. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P100044

Product / regulatory recordCompanyPathwayDecision dateSource
PROPELP100044
Intersect Ent.PMA approvalAug 11, 2011FDA
Intersect Ent.PMA supplementNov 7, 2025FDA
PROPELP100044/S061
Intersect Ent.PMA supplementSep 22, 2026FDA
Intersect Ent.PMA supplementSep 23, 2026FDA

Explore the linked device profile

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Intersect Ent.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
1555 Adams Dr., Menlo Park, CA, 94025

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records